Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej, oboje płci
- •Rozpoznany zaawansowany rak (płuc, jelita grubego, piersi, wątroby, żołądka itd.) kwalifikujący się do immunoterapii
- •Dostępna próbka tkanki do badania
- •Zgodność z protokołem leczenia
- •Dobrowolna zgoda pacjenta na udział w badaniu
✗ Disqualifies
- •Pacjent już rozpoczął immunoterapię przed wpisaniem do badania
- •Pacjent już rozpoczął chemioterapię przed wpisaniem do badania
- •Zaburzenia zdrowia psychicznego lub ogólnego mogące utrudniać udział w badaniu
- •Brak zgody pacjenta na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- January 16, 2026
- Sex
- No restrictions
Locations (2)
University of Medicine and Pharmacy at HCMC
Ho Chi Minh City, Vietnam
Medical Genetics Institute
Ho Chi Minh City, Vietnam
Trial contact
Lan NL Tu, PHD
VAN T Phan, MSc
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.